San Diego’s molecular diagnostic firm BioTheranostics announced Tuesday an agreement with DeNovo Sciences to investigate the feasibility of using BioTheranostics’ proprietary biomarkers for blood-based cancer diagnostics.

The partners plan to perform proof-of-concept studies using DeNovo's Jetta circulating tumor cell (CTC) enrichment and single-cell analysis platform to enable the blood-based detection of undisclosed markers in BioTheranostics portfolio.

If successful, these initial studies could lead to the development of CTC-based liquid biopsy assays.

DeNovo Sciences develops automated systems for rare CTC enrichment and single-cell analysis, namely the label-free Jetta 400 system, which it says performs all the required processing steps to isolate and execute downstream single-cell analysis including immunochemistry, DNA FISH, and mRNA FISH.